Catalent Pharma Solutions has acquired an exclusive license to market Redwood Bioscience’s SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs). Redwood’s site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability.   Catalent will have the exclusive right to sub-license the SMARTag technology to customers and will work with Red...